This trial is testing a new drug, STK-012, to see if it can shrink solid tumors. The trial will test STK-012 alone and in combination with another drug, pembrolizumab.
2 Primary · 8 Secondary · Reporting Duration: Up to 24 months
Experimental Treatment
202 Total Participants · 7 Treatment Groups
Primary Treatment: STK-012 · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: